(AOF) – Genoway announces that it has more than doubled its net profit in 2023 to 1.56 million euros (+102% over one year). This company specializing in the design of predictive preclinical solutions to enable its clients to select their most effective and safest drug candidate shows revenue growth of 18% to 20.04 million euros, and an Ebitda which jumped 54% to 2.06 million. Genoway forecasts that its 2024 financial year should be part of a growth dynamic similar to 2023, “still driven by the development of the Catalog model offering”.
“The 2023 results once again demonstrate the success of our first 2019-2024 strategic plan focused on the development of a catalog of preclinical research models intended for the immuno-oncology market,” declares Managing Director Alexandre Fraichard. “This plan will have enabled the company to double in size, going from 9.5 million euros in turnover in 2019 to 20.0 million euros in 2023, with exclusively organic growth of 20% in average per year over the last four years.
He underlines that this plan “was also accompanied by a strong improvement in our profitability with an EBITDA margin which increased from 6% in 2019 to 23% in 2023”
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
